

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Trilorale 10 mg/ml oral suspension for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance: Trilostane 10 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Sorbitol liquid (non-crystallising)	
Glycerol	
Water, purified	
Xanthan gum	
Sodium benzoate	1.5 mg
Saccharin sodium	
Xylitol	
Sodium dihydrogen phosphate dihydrate	
Citric acid monohydrate or citric acid anhydrous	
Silica, colloidal anhydrous	
Vanillin	

White to off-white suspension.

3. CLINICAL INFORMATION

3.1 Target species

Dogs

3.2 Indications for use for each target species

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs.

3.3 Contraindications

Do not use in animals suffering from primary hepatic disease and/or renal insufficiency.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

An accurate diagnosis of hyperadrenocorticism is essential.

Where there is no apparent response to treatment, the diagnosis should be re-evaluated. Dose increases may be necessary.

Veterinarians should be aware that dogs with hyperadrenocorticism are at increased risk of pancreatitis. This risk may not diminish following treatment with trilostane.

3.5 Special precautions for use

Special precautions for safe use in the target species:

As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases.

Subsequent close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine.

The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring. If a dog has previously been treated with mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least a month should elapse between cessation of mitotane and the introduction of trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of trilostane.

The veterinary medicinal product should be used with extreme caution in dogs with pre-existing anaemias as further reductions in packed-cell volume and haemoglobin may occur. Regular monitoring should be undertaken.

The veterinary medicinal product contains the excipient xylitol which may be a cause of adverse effects if administered at high doses. Administration of Trilorale 10 mg/ml oral suspension for dogs at doses in excess of 2 mg trilostane/kg bodyweight has the potential to result in xylitol toxicity. To mitigate this risk in dogs requiring doses higher than 2 mg trilostane/kg, use Trilorale 50 mg/ml oral suspension for dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Trilostane may decrease testosterone synthesis and has anti-progesterone properties. Women who are pregnant or are intending to become pregnant should avoid handling the veterinary medicinal product. Wash hands with soap and water following accidental exposure and after use.

The veterinary medicinal product may cause skin and eye irritation and sensitisation. In the event of accidental contact of the suspension with eyes or skin, wash immediately with plenty of water. If irritation persists, seek medical advice.

People with known hypersensitivity to trilostane, vanillin or sodium benzoate should avoid contact with the veterinary medicinal product.

Accidental ingestion may cause harmful effects, including nausea, vomiting, and diarrhoea. Care should be taken to avoid accidental ingestion, especially by a child. Keep filled syringes away from children and store used syringes out of the sight and reach of children. In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Uncommon (1 to 10 animals / 1,000 animals treated):	Lethargy ² , anorexia ² , vomiting ² , diarrhoea ²
Rare (1 to 10 animals / 10,000 animals treated):	hypoadrenocorticism, hypersalivation. Bloating, ataxia, muscle tremor, skin disorders, renal insufficiency ³ and arthritis ³
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Weakness ² , adrenal necrosis ¹ and sudden death
Undetermined frequency (Cannot be estimated from the available data):	Acute Addisonian crisis (collapse)

¹ May result in hypoadrenocorticism.

² These signs associated with iatrogenic hypoadrenocorticism may occur, particularly if monitoring is not adequate (see section 3.9). Signs are generally reversible within a variable period following withdrawal of treatment.

Lethargy, vomiting, diarrhoea and anorexia have been seen in dogs treated with trilostane in the absence of evidence of hypoadrenocorticism.

³ May be unmasked by treatment with the product.

Treatment may unmask arthritis due to a reduction in endogenous corticosteroid levels.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation

Do not use in pregnant or lactating bitches.

Fertility

Do not use in breeding animals.

3.8 Interaction with other medicinal products and other forms of interaction

The possibility of interactions with other medicinal products has not been specifically studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be receiving concurrent medication. In clinical studies, no interactions were observed. The risk of hyperkalaemia developing should be considered if trilostane is used in conjunction with potassium-sparing diuretics or Angiotensin-converting-enzyme inhibitors (ACE inhibitors). The concurrent use of such drugs should be subject to a risk-benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with trilostane and an ACE inhibitor.

3.9 Administration routes and dosage

Administer orally, once daily, directly into the mouth of the dog at time of feeding.

The starting dose for treatment is approximately 2 mg/kg. Titrate the dose according to individual response as determined by monitoring (see below). If a dose increase is required, slowly increase the once daily dose. Administer the lowest dose necessary to control the clinical signs.

Trilorale 10 mg/ml oral suspension for dogs should not be administered at doses greater than 2 mg trilostane/kg bodyweight. For dogs requiring doses higher than 2 mg trilostane/kg, use Trilorale 50 mg/ml oral suspension for dogs. See section 3.5 Special precautions for safe use in the target species.

Ultimately, if symptoms are not adequately controlled for an entire 24 hour inter-dose period, consider increasing the total daily dose by up to 50% and dividing it equally between morning and evening doses.

A small number of animals may require doses significantly in excess of 10 mg per kg body weight per day. In these situations appropriate additional monitoring should be implemented.

The dose can be calculated as follows:

$$Volume (ml) = \frac{\text{Daily dose } \left(\frac{mg}{kg}\right) \times \text{body weight (kg)}}{10 \left(\frac{mg}{ml}\right)}$$

Monitoring:

Samples should be taken for biochemistry (including electrolytes) and an ACTH stimulation test pre-treatment and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months, following initial diagnosis and after each dose adjustment. It is imperative that ACTH stimulation tests are performed 4–6 hours post-dosing to enable accurate interpretation of results. Dosing in the morning is preferable as this will allow your veterinary surgeon to perform monitoring tests 4-6 hours following administration of the dose. Regular assessment of the clinical progress of the disease should also be made at each of the above time points.

In the event of a non-stimulatory ACTH stimulation test during monitoring, treatment should be stopped for 7 days and then re-started at a lower dose. Repeat the ACTH stimulation test after a further 14 days. If the result is still non-stimulatory, stop treatment until clinical signs of hyperadrenocorticism recur. Repeat the ACTH stimulation test one month after re-starting treatment.

Shake well before use.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdose may lead to signs of hypoadrenocorticism (lethargy, anorexia, vomiting, diarrhoea, cardiovascular signs, collapse). There were no mortalities following chronic administration at 36 mg/kg to healthy dogs, however mortalities may be expected if higher doses are administered to dogs with hyperadrenocorticism.

There is no specific antidote for trilostane. Treatment should be withdrawn and supportive therapy, including corticosteroids, correction of electrolyte imbalances and fluid therapy may be indicated depending on clinical signs.

In cases of acute overdosage, induction of emesis followed by administration of activated charcoal may be beneficial.

Any iatrogenic adrenocortical insufficiency is usually quickly reversed following cessation of treatment. However in a small percentage of dogs, effects may be prolonged. Following a one week withdrawal of trilostane treatment, treatment should be reinstated at a reduced dose rate.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QH02CA01

4.2 Pharmacodynamics

Trilostane selectively and reversibly inhibits the enzyme system 3 beta hydroxysteroid isomerase, thus blocking the production of cortisol, corticosterone and aldosterone. When used to treat hyperadrenocorticism, it reduces the production of glucocorticoid and mineralocorticoid steroids in the adrenal cortex. Circulating concentrations of these steroids are thus reduced. Trilostane also antagonises the activity of exogenous adrenocorticotrophic hormone (ACTH). It has no direct effect on either the central nervous or cardiovascular systems.

4.3 Pharmacokinetics

Pharmacokinetic data in dogs have demonstrated large inter-individual variability. In a pharmacokinetic study in laboratory beagles, AUC ranged from 52 to 281 micrograms/ml/min in fed dogs, and from 16 to 175 micrograms/ml/min in fasted dogs. Generally trilostane is rapidly removed from the plasma with concentrations in the plasma reaching a maximum between 0.5 to 2.5 hours and returning almost to baseline by six to twelve hours after administration. The primary active metabolite of trilostane, ketotrilostane follows a similar pattern. Furthermore, there was no evidence that trilostane or its metabolites accumulated with time. An oral bioavailability study in dogs demonstrated that trilostane was absorbed more extensively when administered with food.

Trilostane has been demonstrated to be excreted primarily in the faeces of the rat, indicating biliary excretion as the major metabolic pathway. In the monkey, trilostane is excreted in equal amounts in the faeces and urine. Results have shown that trilostane is rapidly and well absorbed from the gastrointestinal tract in both the rat and monkey and that it accumulates in the adrenal glands of the rat.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life after first opening the immediate packaging: 6 months

5.3 Special precautions for storage

This veterinary medicinal product does not require any special temperature storage conditions.

5.4 Nature and composition of immediate packaging

High density polyethylene bottle with child resistant polypropylene/high density polyethylene stoppers and a polyethylene plug in a cardboard box.

Pack sizes:

Cardboard box containing one bottle of 30 ml, and a 1-ml and a 5-ml polypropylene measuring syringe

Cardboard box containing one bottle of 90 ml, and a 1-ml and a 5-ml polypropylene measuring syringe

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Axience

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/24/313/001 (30 ml)

EU/2/24/313/002 (90 ml)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 06/05/2024

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary/en>).

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Trilorale 50 mg/ml oral suspension for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance: Trilostane 50 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Sorbitol liquid (non-crystallising)	
Glycerol	
Water, purified	
Xanthan gum	
Sodium benzoate	1.5 mg
Saccharin sodium	
Xylitol	
Sodium dihydrogen phosphate dihydrate	
Citric acid monohydrate or citric acid anhydrous	
Silica, colloidal anhydrous	
Vanillin	

White to off-white suspension.

3. CLINICAL INFORMATION

3.1 Target species

Dogs

3.2 Indications for use for each target species

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs.

3.3 Contraindications

Do not use in animals suffering from primary hepatic disease and/or renal insufficiency.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

An accurate diagnosis of hyperadrenocorticism is essential.

Where there is no apparent response to treatment, the diagnosis should be re-evaluated. Dose increases may be necessary.

Veterinarians should be aware that dogs with hyperadrenocorticism are at increased risk of pancreatitis. This risk may not diminish following treatment with trilostane.

3.5 Special precautions for use

Special precautions for safe use in the target species:

As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases.

Subsequent close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine.

The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring. If a dog has previously been treated with mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least a month should elapse between cessation of mitotane and the introduction of trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of trilostane.

The veterinary medicinal product should be used with extreme caution in dogs with pre-existing anaemias as further reductions in packed-cell volume and haemoglobin may occur. Regular monitoring should be undertaken.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Trilostane may decrease testosterone synthesis and has anti-progesterone properties. Women who are pregnant or are intending to become pregnant should avoid handling the veterinary medicinal product. Wash hands with soap and water following accidental exposure and after use.

The veterinary medicinal product may cause skin and eye irritation and sensitisation. In the event of accidental contact of the suspension with eyes or skin, wash immediately with plenty of water. If irritation persists, seek medical advice.

People with known hypersensitivity to trilostane, vanillin or sodium benzoate should avoid contact with the veterinary medicinal product.

Accidental ingestion may cause harmful effects, including nausea, vomiting, and diarrhoea. Care should be taken to avoid accidental ingestion, especially by a child. Keep filled syringes away from children and store used syringes out of the sight and reach of children. In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Uncommon (1 to 10 animals / 1,000 animals treated):	Lethargy ² , anorexia ² , vomiting ² , diarrhoea ²
--	--

Rare (1 to 10 animals / 10,000 animals treated):	hypoadrenocorticism, hypersalivation. Bloated, ataxia, muscle tremor, skin disorders, renal insufficiency ³ and arthritis ³
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Weakness ² , adrenal necrosis ¹ and sudden death
Undetermined frequency (Cannot be estimated from the available data):	Acute Addisonian crisis (collapse)

¹ May result in hypoadrenocorticism.

² These signs associated with iatrogenic hypoadrenocorticism may occur, particularly if monitoring is not adequate (see section 3.9). Signs are generally reversible within a variable period following withdrawal of treatment.

Lethargy, vomiting, diarrhoea and anorexia have been seen in dogs treated with trilostane in the absence of evidence of hypoadrenocorticism.

³ May be unmasked by treatment with the product.

Treatment may unmask arthritis due to a reduction in endogenous corticosteroid levels.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation

Do not use in pregnant or lactating bitches.

Fertility

Do not use in breeding animals.

3.8 Interaction with other medicinal products and other forms of interaction

The possibility of interactions with other medicinal products has not been specifically studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be receiving concurrent medication. In clinical studies, no interactions were observed. The risk of hyperkalaemia developing should be considered if trilostane is used in conjunction with potassium-sparing diuretics or Angiotensin-converting-enzyme inhibitors (ACE inhibitors). The concurrent use of such drugs should be subject to a risk-benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with trilostane and an ACE inhibitor.

3.9 Administration routes and dosage

Administer orally, once daily, directly into the mouth of the dog at time of feeding.

The starting dose for treatment is approximately 2 mg/kg. Titrate the dose according to individual response as determined by monitoring (see below). If a dose increase is required, slowly increase the once daily dose. Administer the lowest dose necessary to control the clinical signs.

Ultimately, if symptoms are not adequately controlled for an entire 24 hour inter-dose period, consider increasing the total daily dose by up to 50% and dividing it equally between morning and evening doses.

A small number of animals may require doses significantly in excess of 10 mg per kg body weight per day. In these situations appropriate additional monitoring should be implemented. The dose can be calculated as follows:

$$Volume\ (ml) = \frac{\text{Daily dose } \left(\frac{mg}{kg}\right) \times \text{body weight (kg)}}{50 \left(\frac{mg}{ml}\right)}$$

For volumes smaller than 0.1 ml, use another product.

Monitoring:

Samples should be taken for biochemistry (including electrolytes) and an ACTH stimulation test pre-treatment and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months, following initial diagnosis and after each dose adjustment. It is imperative that ACTH stimulation tests are performed 4–6 hours post-dosing to enable accurate interpretation of results. Dosing in the morning is preferable as this will allow your veterinary surgeon to perform monitoring tests 4-6 hours following administration of the dose. Regular assessment of the clinical progress of the disease should also be made at each of the above time points.

In the event of a non-stimulatory ACTH stimulation test during monitoring, treatment should be stopped for 7 days and then re-started at a lower dose. Repeat the ACTH stimulation test after a further 14 days. If the result is still non-stimulatory, stop treatment until clinical signs of hyperadrenocorticism recur. Repeat the ACTH stimulation test one month after re-starting treatment.

Shake well before use.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdose may lead to signs of hypoadrenocorticism (lethargy, anorexia, vomiting, diarrhoea, cardiovascular signs, collapse). There were no mortalities following chronic administration at 36 mg/kg to healthy dogs, however mortalities may be expected if higher doses are administered to dogs with hyperadrenocorticism.

There is no specific antidote for trilostane. Treatment should be withdrawn and supportive therapy, including corticosteroids, correction of electrolyte imbalances and fluid therapy may be indicated depending on clinical signs.

In cases of acute overdosage, induction of emesis followed by administration of activated charcoal may be beneficial.

Any iatrogenic adrenocortical insufficiency is usually quickly reversed following cessation of treatment. However in a small percentage of dogs, effects may be prolonged. Following a one week withdrawal of trilostane treatment, treatment should be reinstated at a reduced dose rate.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QH02CA01

4.2 Pharmacodynamics

Trilostane selectively and reversibly inhibits the enzyme system 3 beta hydroxysteroid isomerase, thus blocking the production of cortisol, corticosterone and aldosterone. When used to treat hyperadrenocorticism, it reduces the production of glucocorticoid and mineralocorticoid steroids in the adrenal cortex. Circulating concentrations of these steroids are thus reduced. Trilostane also antagonises the activity of exogenous adrenocorticotrophic hormone (ACTH). It has no direct effect on either the central nervous or cardiovascular systems.

4.3 Pharmacokinetics

Pharmacokinetic data in dogs have demonstrated large inter-individual variability. In a pharmacokinetic study in laboratory beagles, AUC ranged from 52 to 281 micrograms/ml/min in fed dogs, and from 16 to 175 micrograms/ml/min in fasted dogs. Generally trilostane is rapidly removed from the plasma with concentrations in the plasma reaching a maximum between 0.5 to 2.5 hours and returning almost to baseline by six to twelve hours after administration. The primary active metabolite of trilostane, ketotrilostane follows a similar pattern. Furthermore, there was no evidence that trilostane or its metabolites accumulated with time. An oral bioavailability study in dogs demonstrated that trilostane was absorbed more extensively when administered with food.

Trilostane has been demonstrated to be excreted primarily in the faeces of the rat, indicating biliary excretion as the major metabolic pathway. In the monkey, trilostane is excreted in equal amounts in the faeces and urine. Results have shown that trilostane is rapidly and well absorbed from the gastrointestinal tract in both the rat and monkey and that it accumulates in the adrenal glands of the rat.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Shelf life after first opening the immediate packaging: 6 months

5.3 Special precautions for storage

This veterinary medicinal product does not require any special temperature storage conditions.

5.4 Nature and composition of immediate packaging

High density polyethylene bottle with child resistant polypropylene/high density polyethylene stoppers and a polyethylene plug in a cardboard box.

Pack sizes:

Cardboard box containing one bottle of 10 ml and a 1-ml and a 5-ml polypropylene measuring syringe
Cardboard box containing one bottle of 25 ml and a 1-ml and a 5-ml polypropylene measuring syringe
Cardboard box containing one bottle of 36 ml and a 1-ml and a 5-ml polypropylene measuring syringe
Cardboard box containing one bottle of 50 ml and a 1-ml and a 5-ml polypropylene measuring syringe
Cardboard box containing one bottle of 72 ml and a 1-ml and a 5-ml polypropylene measuring syringe
Cardboard box containing one bottle of 100 ml and a 1-ml and a 5-ml polypropylene measuring syringe

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Axience

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/24/313/003 (10 ml)
EU/2/24/313/004 (25 ml)
EU/2/24/313/005 (36 ml)
EU/2/24/313/006 (50 ml)
EU/2/24/313/007 (72 ml)
EU/2/24/313/008 (100 ml)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 06/05/2024

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary/en>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box – 10 mg/ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Trilorale 10 mg/ml oral suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Trilostane 10 mg/ml

3. PACKAGE SIZE

30 ml

90 ml

1 ml and 5 ml oral syringe

4. TARGET SPECIES

Dogs

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 6 months.

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”
--

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Axience

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/24/313/001 (30 ml)

EU/2/24/313/002 (90 ml)

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**HDPE/BOTTLE (10 mg/ml – 90 ml)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Trilorale 10 mg/ml oral suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Trilostane 10 mg/ml

3. TARGET SPECIES

Dogs

4. ROUTES OF ADMINISTRATION

Oral use. Read the package leaflet before use.

5. WITHDRAWAL PERIODS**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened use within 6 months.

7. SPECIAL STORAGE PRECAUTIONS**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Axience

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

HDPE/BOTTLE (10 mg/ml – 30 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Trilorale

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Trilostane 10 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 6 months.

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box – 50 mg/ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Trilorale 50 mg/ml oral suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Trilostane 50 mg/ml

3. PACKAGE SIZE

10ml

25ml

36ml

50ml

72ml

100ml

1 ml and 5 ml oral syringe

4. TARGET SPECIES

Dogs

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Oral use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened, use within 6 months

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”
--

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”
--

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Axience

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/24/313/003 (10 ml)
EU/2/24/313/004 (25 ml)
EU/2/24/313/005 (36 ml)
EU/2/24/313/006 (50 ml)
EU/2/24/313/007 (72 ml)
EU/2/24/313/008 (100 ml)

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**HDPE/BOTTLE (50 mg/ml – 72 ml and 100 ml)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Trilorale 50 mg/ml oral suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Trilostane 50 mg/ml

3. TARGET SPECIES

Dogs

4. ROUTES OF ADMINISTRATION

Oral use. Read the package leaflet before use.

5. WITHDRAWAL PERIODS**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened use within 6 months

7. SPECIAL STORAGE PRECAUTIONS**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Axience

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**HDPE/BOTTLE (50 mg/ml – 10 ml, 25 ml, 36 ml, 50 ml)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Trilorale

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Trilostane 50 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 6 months.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Trilorale 10 mg/ml oral suspension for dogs

2. Composition

Each ml contains:

Active substance: Trilostane 10 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Sodium benzoate	1.5 mg

White to off-white suspension.

3. Target species

Dogs

4. Indications for use

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs.

5. Contraindications

Do not use in animals suffering from primary hepatic disease and/or renal insufficiency.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special warnings:

An accurate diagnosis of hyperadrenocorticism is essential.

Where there is no apparent response to treatment, the diagnosis should be re-evaluated. Dose increases may be necessary.

Veterinarians should be aware that dogs with hyperadrenocorticism are at increased risk of pancreatitis. This risk may not diminish following treatment with trilostane.

Special precautions for safe use in the target species:

As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases.

Subsequent close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine.

The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring. If a dog has previously been treated with mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least a month should elapse between cessation of mitotane and the introduction of trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of trilostane.

The veterinary medicinal product should be used with extreme caution in dogs with pre-existing anaemias as further reductions in packed-cell volume and haemoglobin may occur. Regular monitoring should be undertaken.

The veterinary medicinal product contains the excipient xylitol which may be a cause of adverse effects if administered at high doses. Administration of Trilorale 10 mg/ml oral suspension for dogs at doses in excess of 2 mg trilostane/kg bodyweight has the potential to result in xylitol toxicity. To mitigate this risk in dogs requiring doses higher than 2 mg trilostane/kg, use Trilorale 50 mg/ml oral suspension for dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Trilostane may decrease testosterone synthesis and has anti-progesterone properties. Women who are pregnant or are intending to become pregnant should avoid handling the veterinary medicinal product. Wash hands with soap and water following accidental exposure and after use.

The veterinary medicinal product may cause skin and eye irritation and sensitisation. In the event of accidental contact of the suspension with eyes or skin, wash immediately with plenty of water. If irritation persists, seek medical advice.

People with known hypersensitivity to trilostane, vanillin or sodium benzoate should avoid contact with the veterinary medicinal product.

Accidental ingestion may cause harmful effects, including nausea, vomiting, and diarrhoea. Care should be taken to avoid accidental ingestion, especially by a child. Keep filled syringes away from children and store used syringes out of the sight and reach of children.

In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or carton to the physician.

Pregnancy and lactation:

Do not use in pregnant or lactating bitches.

Fertility:

Do not use in breeding animals.

Interaction with other medicinal products and other forms of interaction:

The possibility of interactions with other medicinal products has not been specifically studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be receiving concurrent medication. In clinical studies, no interactions were observed. The risk of hyperkalaemia developing should be considered if trilostane is used in conjunction with potassium-sparing diuretics or Angiotensin-converting-enzyme inhibitors (ACE inhibitors). The concurrent use of such drugs should be subject to a risk-benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with trilostane and an ACE inhibitor.

Overdose:

Overdose may lead to signs of hypoadrenocorticism (lethargy, anorexia, vomiting, diarrhoea, cardiovascular signs, collapse). There were no mortalities following chronic administration at 36 mg/kg to healthy dogs, however mortalities may be expected if higher doses are administered to dogs with hyperadrenocorticism.

There is no specific antidote for trilostane. Treatment should be withdrawn and supportive therapy, including corticosteroids, correction of electrolyte imbalances and fluid therapy may be indicated depending on clinical signs.

In cases of acute overdosage, induction of emesis followed by administration of activated charcoal may be beneficial.

Any iatrogenic adrenocortical insufficiency is usually quickly reversed following cessation of treatment. However in a small percentage of dogs, effects may be prolonged. Following a one week withdrawal of trilostane treatment, treatment should be reinstated at a reduced dose rate.

7. Adverse events

Dogs:

Uncommon (1 to 10 animals / 1,000 animals treated):	Lethargy ² , anorexia ² , vomiting ² , diarrhoea ²
Rare (1 to 10 animals / 10,000 animals treated):	hypoadrenocorticism, hypersalivation. Bloated, ataxia, muscle tremor, skin disorders, renal insufficiency ³ and arthritis ³
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Weakness ² , adrenal necrosis ¹ and sudden death
Undetermined frequency (Cannot be estimated from the available data):	Acute Addisonian crisis (collapse)

¹ May result in hypoadrenocorticism.

² These signs associated with iatrogenic hypoadrenocorticism may occur, particularly if monitoring is not adequate (see section 'Dosage for each species, routes and method of administration'). Signs are generally reversible within a variable period following withdrawal of treatment. Lethargy, vomiting, diarrhoea and anorexia have been seen in dogs treated with trilostane in the absence of evidence of hypoadrenocorticism.

³ May be unmasked by treatment with the product.

Treatment may unmask arthritis due to a reduction in endogenous corticosteroid levels.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Administer orally, once daily, directly into the mouth of the dog, at time of feed.

The starting dose for treatment is approximately 2 mg/kg. Titrate the dose according to individual response as determined by monitoring (see below). If a dose increase is required, slowly increase the once daily dose. Administer the lowest dose necessary to control the clinical signs.

If doses higher than 2 mg trilostane/kg are required, use “Trilorale 50 mg/ml oral suspension for dogs”.

Ultimately, if symptoms are not adequately controlled for an entire 24 hour inter-dose period, consider increasing the total daily dose by up to 50% and dividing it equally between morning and evening doses.

A small number of animals may require doses significantly in excess of 10 mg per kg body weight per day. In these situations appropriate additional monitoring should be implemented.

The dose can be calculated as follows:

$$Volume (ml) = \frac{\text{Daily dose } \left(\frac{\text{mg}}{\text{kg}}\right) \times \text{body weight (kg)}}{10 \left(\frac{\text{mg}}{\text{ml}}\right)}$$

Monitoring:

Samples should be taken for biochemistry (including electrolytes) and an ACTH stimulation test pre-treatment and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months, following initial diagnosis and after each dose adjustment. It is imperative that ACTH stimulation tests are performed 4–6 hours post-dosing to enable accurate interpretation of results. Dosing in the morning is preferable as this will allow your veterinary surgeon to perform monitoring tests 4-6 hours following administration of the dose. Regular assessment of the clinical progress of the disease should also be made at each of the above time points.

In the event of a non-stimulatory ACTH stimulation test during monitoring, treatment should be stopped for 7 days and then re-started at a lower dose. Repeat the ACTH stimulation test after a further 14 days. If the result is still non-stimulatory, stop treatment until clinical signs of hyperadrenocorticism recur. Repeat the ACTH stimulation test one month after re-starting treatment.

Shake well before use.

9. Advise on correct administration

None.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 6 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Pack sizes:

EU/2/24/313/001 - Cardboard box containing one bottle of 30 ml, and a 1-ml and a 5-ml polypropylene measuring syringe

EU/2/24/313/002 - Cardboard box containing one bottle of 90 ml, and a 1-ml and a 5-ml polypropylene measuring syringe

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

<{MM/YYYY}>

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary/en>).

16. Contact details

Marketing authorisation holder:

Axience
Tour essor, 14 rue Scandicci
93500 Pantin
France

Manufacturer responsible for batch release:

Lelypharma bv
Zuiveringsweg 42
8243 PZ Lelystad
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin
Frankrijk/France/Frankreich
Tél: + 33 141832310
pharmacovigilance@axience.fr

Република България

VETWEST LTD
10 Poduevo Str
BG 1113-Sofia- Bŭlgariya
Тел: + 359 888713685
ortho@vetwest.eu

Česká republika

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francie
Tél: + 33 141832310
pharmacovigilance@axience.fr

Danmark

Salfarm Danmark A/S
Nordager 19,
DK-6000 Kolding - Danmark
Tlf: +45 75 50 80 80
info@salfarm.com

Deutschland

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Franckreich
Tél: + 33 141832310
pharmacovigilance@axience.fr

Eesti

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Prantsusmaa
Tél: + 33 141832310
pharmacovigilance@axience.fr

Ελλάδα

Neocell Ltd
Veterinary Pharmaceuticals
10th klm Athens-Lamia
144 51, Metamorfosi
Athens, Greece
Τηλ: +30 210 2844333

Lietuva

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Prancūzija
Tél: + 33 141832310
pharmacovigilance@axience.fr

Luxembourg/Luxemburg

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - France
Tél: + 33 141832310
pharmacovigilance@axience.fr

Magyarország

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Franciaország
Tél: + 33 141832310
pharmacovigilance@axience.fr

Malta

Borg Cardona & Co. Ltd
Eltex, Dr. J. Zammit Street,
Balzan BZN 1434 - MALTA
Tel: + 356 79941977
regulatory@borgcardona.com.mt

Nederland

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Frankrijk
Tél: + 33 141832310
pharmacovigilance@axience.fr

Norge

Salfarm Scandinavia AS
Fridtjof Nansens Plass 4,
N-0160, Oslo - Norge
Tlf: +47 902 97 102
norge@salfarm.com

Österreich

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Frankreich
Tél: + 33 141832310
pharmacovigilance@axience.fr

España

Ecuphar Veterinaria SLU
C/Cerdanya, 10-12 Planta 6º
ES- 08173 Sant Cugat del Vallés,
Barcelona - España
Tel: +34 935955000
Email: info@ecuphar.es

France

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin- France
Tél: + 33 141832310
pharmacovigilance@axience.fr

Hrvatska

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francuska
Tél: + 33 141832310
pharmacovigilance@axience.fr

Ireland

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - France
Tél: + 33 141832310
pharmacovigilance@axience.fr

Ísland

Salfarm Danmark A/S
Nordager 19,
DK-6000 Kolding - Danmark
Sími: +45 75 50 80 80
info@salfarm.com

Italia

Ecuphar Italia S.r.l.
Viale Francesco Restelli, 3/7
IT-20124 Milano - Italia
Tel: +39 0282950604
E-mail: info@ecuphar.it

Κύπρος

T.C.Christoforou Ltd.
12 Klimis Street, Agiou Fanouriou,
Aradippou Industrial Area
CY-7101 Larnaca - Kýpros
Τηλ: + 35799560155
drug.safety@tcc.com.cy

Polska

ScanVet Poland Sp. z. o.o.
Al. Jerozolimskie 99 m.39
PL – 02-001 Warszawa - Polska
Tel.: + 48667689681
pharmacovigilance@scanvet.pl

Portugal

Belphar Lda
Sintra Business Park 7, Edifício 1,
Escritório 2K
Zona Industrial de Abrunheira
PT-2710-089 Sintra - Portugal
Tel: +351 308808321
E-mail: info@ecuphar.pt

România

SC MONTERO VET SRL
Celofibrei Street 25-27
Bragadiru/Ilfov - România
Tél: + 40 729 290 738
mihaela.iacob@monterovet.ro

Slovenija

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francija
Tél: + 33 141832310
pharmacovigilance@axience.fr

Slovenská republika

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francúzsko
Tél: + 33 141832310
pharmacovigilance@axience.fr

Suomi/Finland

Salfarm Danmark A/S
Nordager 19,
DK-6000 Kolding - Danmark
Tlf: +45 75 50 80 80
info@salfarm.com

Sverige

Salfarm Scandinavia AB
Florettgatan 29C,
SE-254 67 Helsingborg -Sverige
Tel: +46 767 834 810
scan@salfarm.com

Latvija

Axience

Tour Eссор - 14, rue Scandicci

FR-93500 Pantin - Francija

Tél: + 33 141832310

pharmacovigilance@axience.fr

United Kingdom (Northern Ireland)

Ecuphar NV

Legeweg 157-i

B-8020 Oostkamp - Belgium

Tel: +32 50314269

E-mail: info@ecuphar.be

1. Name of the veterinary medicinal product

Trilorale 50 mg/ml oral suspension for dogs

2. Composition

Each ml contains:

Active substance: Trilostane 50 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Sodium benzoate	1.5 mg

White to off-white suspension.

3. Target species

Dogs

4. Indications for use

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs.

5. Contraindications

Do not use in animals suffering from primary hepatic disease and/or renal insufficiency.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special warnings:

An accurate diagnosis of hyperadrenocorticism is essential.

Where there is no apparent response to treatment, the diagnosis should be re-evaluated. Dose increases may be necessary.

Veterinarians should be aware that dogs with hyperadrenocorticism are at increased risk of pancreatitis. This risk may not diminish following treatment with trilostane.

Special precautions for safe use in the target species:

As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases.

Subsequent close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine.

The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring. If a dog has previously been treated with mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least a month should elapse between cessation of mitotane and the introduction of trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of trilostane.

The veterinary medicinal product should be used with extreme caution in dogs with pre-existing anaemias as further reductions in packed-cell volume and haemoglobin may occur. Regular monitoring should be undertaken.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Trilostane may decrease testosterone synthesis and has anti-progesterone properties. Women who are pregnant or are intending to become pregnant should avoid handling the veterinary medicinal product. Wash hands with soap and water following accidental exposure and after use.

The veterinary medicinal product may cause skin and eye irritation and sensitisation. In the event of accidental contact of the suspension with eyes or skin, wash immediately with plenty of water. If irritation persists, seek medical advice.

People with known hypersensitivity to trilostane, vanillin or sodium benzoate should avoid contact with the veterinary medicinal product.

Accidental ingestion may cause harmful effects, including nausea, vomiting, and diarrhoea. Care should be taken to avoid accidental ingestion, especially by a child. Keep filled syringes away from children and store used syringes out of the sight and reach of children.

In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or carton to the physician.

Pregnancy and lactation:

Do not use in pregnant or lactating bitches.

Fertility:

Do not use in breeding animals.

Interaction with other medicinal products and other forms of interaction:

The possibility of interactions with other medicinal products has not been specifically studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be receiving concurrent medication. In clinical studies, no interactions were observed. The risk of hyperkalaemia developing should be considered if trilostane is used in conjunction with potassium-sparing diuretics or Angiotensin-converting-enzyme inhibitors (ACE inhibitors). The concurrent use of such drugs should be subject to a risk-benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with trilostane and an ACE inhibitor.

Overdose:

Overdose may lead to signs of hypoadrenocorticism (lethargy, anorexia, vomiting, diarrhoea, cardiovascular signs, collapse). There were no mortalities following chronic administration at 36 mg/kg to healthy dogs, however mortalities may be expected if higher doses are administered to dogs with hyperadrenocorticism.

There is no specific antidote for trilostane. Treatment should be withdrawn and supportive therapy, including corticosteroids, correction of electrolyte imbalances and fluid therapy may be indicated depending on clinical signs.

In cases of acute overdosage, induction of emesis followed by administration of activated charcoal may be beneficial.

Any iatrogenic adrenocortical insufficiency is usually quickly reversed following cessation of treatment. However in a small percentage of dogs, effects may be prolonged. Following a one week withdrawal of trilostane treatment, treatment should be reinstated at a reduced dose rate.

7. Adverse events

Dogs:

Uncommon (1 to 10 animals / 1,000 animals treated):	Lethargy ² , anorexia ² , vomiting ² , diarrhoea ²
Rare (1 to 10 animals / 10,000 animals treated):	hypoadrenocorticism, hypersalivation. Bloating, ataxia, muscle tremor, skin disorders, renal insufficiency ³ and arthritis ³
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Weakness ² , adrenal necrosis ¹ and sudden death
Undetermined frequency (Cannot be estimated from the available data):	Acute Addisonian crisis (collapse)

¹ May result in hypoadrenocorticism.

² These signs associated with iatrogenic hypoadrenocorticism may occur, particularly if monitoring is not adequate (see section 'Dosage for each species, routes and method of administration'). Signs are generally reversible within a variable period following withdrawal of treatment.

Lethargy, vomiting, diarrhoea and anorexia have been seen in dogs treated with trilostane in the absence of evidence of hypoadrenocorticism.

³ May be unmasked by treatment with the product.

Treatment may unmask arthritis due to a reduction in endogenous corticosteroid levels.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Administer orally, once daily, directly into the mouth of the dog, at time of feed.

The starting dose for treatment is approximately 2 mg/kg. Titrate the dose according to individual response as determined by monitoring (see below). If a dose increase is required, slowly increase the once daily dose. Administer the lowest dose necessary to control the clinical signs.

Ultimately, if symptoms are not adequately controlled for an entire 24 hour inter-dose period, consider increasing the total daily dose by up to 50% and dividing it equally between morning and evening doses.

A small number of animals may require doses significantly in excess of 10 mg per kg body weight per day. In these situations appropriate additional monitoring should be implemented.

The dose can be calculated as follows:

$$Volume (ml) = \frac{\text{Daily dose } \left(\frac{mg}{kg}\right) \times \text{body weight (kg)}}{50 \left(\frac{mg}{ml}\right)}$$

For volumes smaller than 0.1 ml, use another product.

Monitoring:

Samples should be taken for biochemistry (including electrolytes) and an ACTH stimulation test pre-treatment and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months, following initial diagnosis and after each dose adjustment. It is imperative that ACTH stimulation tests are performed 4– 6 hours post-dosing to enable accurate interpretation of results. Dosing in the morning is preferable as this will allow your veterinary surgeon to perform monitoring tests 4-6 hours following administration of the dose. Regular assessment of the clinical progress of the disease should also be made at each of the above time points.

In the event of a non-stimulatory ACTH stimulation test during monitoring, treatment should be stopped for 7 days and then re-started at a lower dose. Repeat the ACTH stimulation test after a further 14 days. If the result is still non-stimulatory, stop treatment until clinical signs of hyperadrenocorticism recur. Repeat the ACTH stimulation test one month after re-starting treatment.

Shake well before use.

9. Advise on correct administration

None.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 6 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Pack sizes:

EU/2/24/313/003 - Cardboard box containing one bottle of 10 ml, and a 1-ml and a 5-ml polypropylene measuring syringe
EU/2/24/313/004 - Cardboard box containing one bottle of 25 ml, and a 1-ml and a 5-ml polypropylene measuring syringe
EU/2/24/313/005 - Cardboard box containing one bottle of 36 ml, and a 1-ml and a 5-ml polypropylene measuring syringe
EU/2/24/313/006 - Cardboard box containing one bottle of 50 ml, and a 1-ml and a 5-ml polypropylene measuring syringe
EU/2/24/313/007 - Cardboard box containing one bottle of 72 ml, and a 1-ml and a 5-ml polypropylene measuring syringe
EU/2/24/313/008 - Cardboard box containing one bottle of 100 ml, and a 1-ml and a 5-ml polypropylene measuring syringe

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

<{MM/YYYY}>

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary/en>).

16. Contact details

Marketing authorisation holder:

Axience
Tour essor, 14 rue Scandicci
93500 Pantin
France

Manufacturer responsible for batch release:

Lelypharma bv
Zuiveringsweg 42
8243 PZ Lelystad
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Axience
Tour Essor - 14, rue Scandicci
FR-93500 Pantin
Frankrijk/France/Frankreich
Tél: + 33 141832310
pharmacovigilance@axience.fr

Lietuva

Axience
Tour Essor - 14, rue Scandicci
FR-93500 Pantin - Prancūzija
Tél: + 33 141832310
pharmacovigilance@axience.fr

Република България
VETWEST LTD
10 Poduevo Str
BG 1113-Sofia- Bŭlgariya
Тел: + 359 888713685
ortho@vetwest.eu

Česká republika
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francie
Тél: + 33 141832310
pharmacovigilance@axience.fr

Danmark
Salfarm Danmark A/S
Nordager 19,
DK-6000 Kolding - Danmark
Tlf: +45 75 50 80 80
info@salfarm.com

Deutschland
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Franckreich
Тél: + 33 141832310
pharmacovigilance@axience.fr

Eesti
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Prantsusmaa
Тél: + 33 141832310
pharmacovigilance@axience.fr

Ελλάδα
Neocell Ltd
Veterinary Pharmaceuticals
10th klm Athens-Lamia
144 51, Metamorfosi
Athens, Greece
Τηλ: +30 210 2844333

España
Ecuphar Veterinaria SLU
C/Cerdanya, 10-12 Planta 6º
ES- 08173 Sant Cugat del Vallés,
Barcelona - España
Tel: +34 935955000
Email: info@ecuphar.es

Luxembourg/Luxemburg
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - France
Тél: + 33 141832310
pharmacovigilance@axience.fr

Magyarország
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Franciaország
Тél: + 33 141832310
pharmacovigilance@axience.fr

Malta
Borg Cardona & Co. Ltd
Eltex, Dr. J. Zammit Street,
Balzan BZN 1434 - MALTA
Tel: + 356 79941977
regulatory@borgcardona.com.mt

Nederland
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Frankrijk
Тél: + 33 141832310
pharmacovigilance@axience.fr

Norge
Salfarm Scandinavia AS
Fridtjof Nansens Plass 4,
N-0160, Oslo - Norge
Tlf: +47 902 97 102
norge@salfarm.com

Österreich
Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Frankreich
Тél: + 33 141832310
pharmacovigilance@axience.fr

Polska
ScanVet Poland Sp. z. o.o.
Al. Jerozolimskie 99 m.39
PL – 02-001 Warszawa - Polska
Tel.: + 48667689681
pharmacovigilance@scanvet.pl

France

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin- France
Tél: + 33 141832310
pharmacovigilance@axience.fr

Hrvatska

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francuska
Tél: + 33 141832310
pharmacovigilance@axience.fr

Ireland

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - France
Tél: + 33 141832310
pharmacovigilance@axience.fr

Ísland

Salfarm Danmark A/S
Nordager 19,
DK-6000 Kolding - Danmark
Sími: +45 75 50 80 80
info@salfarm.com

Italia

Ecuphar Italia S.r.l.
Viale Francesco Restelli, 3/7
IT-20124 Milano - Italia
Tel: +39 0282950604
E-mail: info@ecuphar.it

Κύπρος

T.C.Christoforou Ltd.
12 Klimis Street, Agiou Fanouriou,
Aradippou Industrial Area
CY-7101 Larnaca - Kýpros
Τηλ: + 35799560155
drug.safety@tcc.com.cy

Latvija

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francija
Tél: + 33 141832310
pharmacovigilance@axience.fr

Portugal

Belphar Lda
Sintra Business Park 7, Edifício 1,
Escritório 2K
Zona Industrial de Abrunheira
PT-2710-089 Sintra - Portugal
Tel: +351 308808321
E-mail: info@ecuphar.pt

România

SC MONTERO VET SRL
Celofibrei Street 25-27
Bragadiru/Ilfov - România
Tél: + 40 729 290 738
mihaela.iacob@monterovet.ro

Slovenija

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francija
Tél: + 33 141832310
pharmacovigilance@axience.fr

Slovenská republika

Axience
Tour Eссор - 14, rue Scandicci
FR-93500 Pantin - Francúzsko
Tél: + 33 141832310
pharmacovigilance@axience.fr

Suomi/Finland

Salfarm Danmark A/S
Nordager 19,
DK-6000 Kolding - Danmark
Tlf: +45 75 50 80 80
info@salfarm.com

Sverige

Salfarm Scandinavia AB
Florettgatan 29C,
SE-254 67 Helsingborg -Sverige
Tel: +46 767 834 810
scan@salfarm.com

United Kingdom (Northern Ireland)

Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp - Belgium
Tel: +32 50314269
E-mail: info@ecuphar.be